WO2014199698A1 - Agent d'élévation de la température corporelle - Google Patents

Agent d'élévation de la température corporelle Download PDF

Info

Publication number
WO2014199698A1
WO2014199698A1 PCT/JP2014/058520 JP2014058520W WO2014199698A1 WO 2014199698 A1 WO2014199698 A1 WO 2014199698A1 JP 2014058520 W JP2014058520 W JP 2014058520W WO 2014199698 A1 WO2014199698 A1 WO 2014199698A1
Authority
WO
WIPO (PCT)
Prior art keywords
body temperature
increasing agent
present
agent
temperature increasing
Prior art date
Application number
PCT/JP2014/058520
Other languages
English (en)
Japanese (ja)
Inventor
勝隆 大石
幸織 山本
奈々子 伊藤
歴 宮崎
保一 中北
弘挙 金田
Original Assignee
独立行政法人産業技術総合研究所
サッポロホールディングス株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 独立行政法人産業技術総合研究所, サッポロホールディングス株式会社 filed Critical 独立行政法人産業技術総合研究所
Publication of WO2014199698A1 publication Critical patent/WO2014199698A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/50—Feeding-stuffs specially adapted for particular animals for rodents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Definitions

  • the present invention relates to a body temperature raising agent.
  • Patent Document 1 describes that lactic acid bacteria Lactobacillus paracasei ST11 strain has an effect of increasing body temperature.
  • the strain described in Patent Document 1 describes that the body temperature rises by about 1.5 ° C. in a short time of about 60 minutes after ingesting the strain. At such a level of body temperature rise, when a normal heat person ingests the above strain, the body temperature rises to a fever state and is not suitable as a body temperature raising agent.
  • an object of the present invention is to provide a novel body temperature increasing agent having a moderate body temperature increasing effect.
  • the present inventors have found that a strain of Lactobacillus brevis SBC8803, which is a lactic acid bacterium, or a processed product thereof has an action of appropriately increasing body temperature.
  • the present invention is based on this novel finding.
  • the present invention provides a body temperature raising agent containing, as an active ingredient, a cell of SBC8803 belonging to Lactobacillus brevis or a processed product thereof.
  • the body temperature increasing agent the body temperature can be increased moderately. Therefore, for example, it is effective for raising the body temperature of a person having a low body temperature to an appropriate body temperature.
  • the Lactobacillus brevis SBC8803 strain was founded on June 28, 2006 at the National Institute of Advanced Industrial Science and Technology, Patent Biological Depositary Center (1st East, 1-chome, Tsukuba City, Ibaraki, Japan, 6th postal code (305-8586)). ), And the accession number is FERM BP-10632. In the present specification, this strain is also referred to as “SBL88 strain”.
  • the said body temperature raising agent has an effect as mentioned above, it can be used also as a cooling improvement agent, for example.
  • the present inventors also have the effect that the strain of SBL88 strain or the processed product itself has an action of suppressing a decrease in body temperature under stress such as stressful sleep disorder, lifestyle disturbance, body temperature disorder due to excessive cooling, etc. I also found. Therefore, the said body temperature increasing agent can be used also as a body temperature fall inhibitor.
  • the present invention can also be referred to as an agent for increasing body temperature, which contains the above-mentioned cells or a processed product thereof as an active ingredient.
  • the present invention can also be referred to as a method for increasing body temperature, which comprises administering an agent containing the above-mentioned bacterial cell or a processed product thereof as an active ingredient to a treatment subject.
  • the present invention can also be said to be a use for increasing the body temperature of an agent containing the above-mentioned bacterial cell or its treated product as an active ingredient.
  • Lactobacillus brevis is a type of lactic acid bacterium that has been used for fermented foods for a long time, and its safety to living bodies has been established. Therefore, the body temperature increasing agent of the present invention is highly safe to the living body and can be taken continuously for a long period of time. Therefore, it can be used as a pharmaceutical ingredient, a food / beverage product component, a food / beverage product additive, and the like.
  • a novel body temperature increasing agent having an appropriate body temperature increasing effect is provided. Moreover, the pharmaceutical, food / beverage products, food / beverage additive, etc. containing the said body temperature raising agent are provided.
  • the body temperature increasing agent of the present invention contains a cell of SBC8803 belonging to Lactobacillus brevis or a processed product thereof as an active ingredient.
  • the above bacterial cells and the processed product of the above bacterial cells may be used singly or in combination of two or more.
  • the above microbial cells may be either live cells or dead cells. Bacteria can be produced in large quantities by culturing viable bacteria.
  • the medium may be either a liquid medium or a solid medium, but preferably contains a nitrogen source and a carbon source. Nitrogen sources include meat extract, peptone, gluten, casein, yeast extract, amino acids, etc., and carbon sources include glucose, xylose, fructose, inositol, maltose, water candy, soup, starch, bagasse, bran, Molasses, glycerin and the like can be used.
  • Suitable media include MRS media, LBS media, Rogosa media, WYP media, GYP media and the like.
  • the above-mentioned strain can be cultured according to a culture method commonly used for culturing strains belonging to Lactobacillus brevis.
  • the culture temperature is usually 20 to 50 ° C., preferably 25 to 40 ° C., more preferably 30 ° C.
  • the culture time is usually 6 to 62 hours, preferably 12 to 48 hours, more preferably 15 to 30 hours.
  • the pH of the medium is usually 3 to 8, preferably 4 to 7, and more preferably 6 to 7. Cultivation may be performed in an incubator, or aeration and shaking may be performed during the cultivation.
  • treated cells include treated products obtained by subjecting the above-mentioned cells (live cells or dead cells) to treatment such as heating, pressurization, drying, crushing, crushing, breaking, or self-dissolution. . Two or more of these treatments may be combined.
  • a treated product obtained by heating the cells at 100 ° C. or more for several minutes or more for example, the cells are subjected to autoclaving at a temperature of 105 to 125 ° C. for 10 minutes or more. Processed product), processed product obtained by freeze-drying, spray-drying, etc.
  • processed product obtained by contacting the bacterial cells with an organic solvent acetone, ethanol, etc.
  • a treated product obtained by contacting with an alkaline solution, a treated product obtained by enzymatic disruption of bacterial cells, or a treated product obtained by physically destroying the bacterial cells with ultrasonic waves, a French press, or the like can be used.
  • Such a cell-treated product is preferable in that it is easy to handle as compared with untreated cells (particularly live cells).
  • the body temperature increasing agent of the present invention may be in any form such as solid (for example, powder obtained by freeze-drying), liquid (water-soluble or fat-soluble solution or suspension), paste, etc. Any dosage form such as powder, pill, granule, tablet, syrup, troche, capsule and the like may be used.
  • the above-mentioned various preparations may consist only of the above-mentioned fungus bodies or processed products thereof, which are active ingredients, and can be prepared, for example, by molding the fungus bodies or treated products thereof into the above dosage form. .
  • the above-mentioned various preparations also contain the above active ingredients and pharmaceutically acceptable additives (excipients, binders, lubricants, disintegrants, emulsifiers, surfactants, bases, solubilizers, suspensions). It is also possible to prepare the mixture by mixing with an agent and the like. In this case, the content of the active ingredient is, for example, 0.5 to 50% by mass based on the total amount of the preparation.
  • examples of the excipient include lactose, sucrose, starch, dextrin and the like.
  • the binder include polyvinyl alcohol, gum arabic, tragacanth, gelatin, hydroxypropylmethylcellulose, hydroxypropylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone and the like.
  • examples of the lubricant include magnesium stearate, calcium stearate, talc and the like.
  • examples of the disintegrant include crystalline cellulose, agar, gelatin, calcium carbonate, sodium bicarbonate, dextrin and the like.
  • the emulsifier or surfactant include Tween 60, Tween 80, Span 80, and glyceryl monostearate.
  • Examples of the base include cetostearyl alcohol, lanolin, polyethylene glycol, rice bran oil, fish oil (DHA, EPA, etc.), olive oil and the like.
  • Examples of the solubilizer include polyethylene glycol, propylene glycol, sodium carbonate, sodium citrate, Tween 80 and the like.
  • Examples of the suspending agent include Tween 60, Tween 80, Span 80, glyceryl monostearate, polyvinyl alcohol, polyvinyl pyrrolidone, methyl cellulose, hydroxymethyl cellulose, sodium alginate and the like.
  • the body temperature increasing agent of the present invention may be administered to humans or non-human mammals.
  • the dosage and administration method can be appropriately determined according to the condition, age, etc. of the individual to be administered. Suitable administration methods include, for example, oral administration.
  • As an example of the dosage and administration method there can be mentioned a method of orally administering a body temperature increasing agent in an amount of 0.5 to 500 mg of an active ingredient once a day.
  • the body temperature increasing agent of the present invention can be used as a pharmaceutical ingredient, a food / beverage product component, a food / beverage product additive, a feed component, a feed additive, and the like.
  • the body temperature increasing agent of the present invention is water, soft drinks, fruit juice drinks, milk drinks, alcoholic drinks, breads, noodles, rice, tofu, dairy products, fermented foods, fermented milk, soy sauce, miso, confectionery. It can be used as an additive to foods and beverages. These foods and drinks may further contain other additives usually used in the art, and examples of such additives include bitters, flavors, apple fibers, soybean fibers, meat extracts, blacks.
  • the body temperature increasing agent of the present invention can also be used as a component for foods for specified health use, foods for special uses, dietary supplements, health foods, functional foods, foods for the sick, and the like.
  • the said food-drinks can be obtained with the manufacturing method including the process of adding the body temperature increasing agent of this invention.
  • the food and drink containing the body temperature increasing agent of the present invention may be a fermented product obtained by fermenting milk, skim milk, soy milk, vegetables, fruit juice, grains, processed products thereof, and the like with the above strain.
  • the body temperature increasing agent of the present invention has an effect of appropriately increasing body temperature. That is, according to the body temperature increasing agent of the present invention, for example, it can be increased by 0.05 to 0.50 ° C. Therefore, even if ingested by a person with normal heat, the body temperature does not rise to a fever state, and thus can be used as a cold improving agent for improving symptoms such as cold.
  • the body temperature increasing agent of the present invention has an effect of suppressing a decrease in body temperature under stress such as stressful sleep disorder, lifestyle disturbance, body temperature disorder due to excessive cooling or the like.
  • body temperature tends to be lower than that at normal time in these body temperature disorders, by taking the body temperature increasing agent of the present invention, it is possible to suppress a decrease in body temperature and maintain a body temperature closer to normal. Therefore, the body temperature increasing agent of the present invention can be used as a body temperature lowering inhibitor.
  • the present invention can also be referred to as an agent for use in improving cooling or suppressing body temperature reduction, containing the above-mentioned bacterial cell or a processed product thereof as an active ingredient.
  • the present invention can also be referred to as a method for improving cooling or a method for suppressing a decrease in body temperature, which comprises administering an agent containing the above bacterial cell or a processed product thereof as an active ingredient to a treatment subject.
  • the present invention can also be said to be a use for improving the cooling or suppressing the decrease in body temperature of an agent containing the above-mentioned bacterial cell or a processed product thereof as an active ingredient.
  • Example 1 (Test method) ⁇ Preparation of treated cells> SBL88 strain was inoculated in a medium (composition: maltose 2% by mass, yeast extract 1.4% by mass, sodium acetate 0.5% by mass, manganese sulfate 0.005% by mass, pH 6.5-7.0), 30 The culture was allowed to stand at 1 ° C for 1 day. The obtained culture solution (about 8 ⁇ 10 8 cfu / ml) was centrifuged at 8,000 rpm for 10 minutes, and the cells were collected. The collected cells were resuspended in distilled water and centrifuged at 8,000 rpm for 10 minutes to collect the cells. This operation was repeated twice. The collected cells were suspended in distilled water, heat-treated at 105 ° C. for 10 minutes, and then freeze-dried to obtain heat-treated cell powder (cell-treated product).
  • a medium composition: maltose 2% by mass, yeast extract 1.4% by mass, sodium acetate 0.5% by mass, manganese
  • mice were raised in a rotating cage (SW-15S, Merquest Co.). The amount of activity of mice was measured using a chronobiology kit (Stanford Software Systems, CA).
  • mice C3H / HeN strain mice (6 weeks old male, 13 mice, SLC Japan) were bred for 10 days. Three days after the start of habituation breeding, a temperature data logger (Thermocron SL, manufactured by KN Laboratory) was embedded in the abdominal cavity of the mouse. After acclimatization, mice were divided into two groups in order of total activity, AIN-93M feed was used as a diet for 6 animals in the control group, and AIN-93M containing SBL88 as food for 7 animals in the test group (SBL88 group). Feeded and allowed to eat freely.
  • AIN-93M feed was used as a diet for 6 animals in the control group
  • AIN-93M containing SBL88 as food for 7 animals in the test group (SBL88 group). Feeded and allowed to eat freely.
  • ⁇ Measurement of average body temperature> One day after the start of feeding the AIN-93M diet or the AIN-93M diet containing SBL88, body temperature measurement was started using a data logger. The measurement was performed every 15 minutes, and the average body temperature for one day (24 hours) was obtained. The average body temperature of each group was determined as the average body temperature of the mice in each group. The presence or absence of significant difference was compared between groups by the Tukey method after multiple comparison test.
  • FIG. 1 is a graph showing changes in average body temperature of mice in the SBL88 group and the control group during the non-stress breeding period and the stress breeding period.
  • the data marked with * indicates p ⁇ 0.05
  • the data marked with ** indicates p ⁇ 0.01.
  • the SBL88 group showed a statistically significant difference in mean body temperature compared to the control group.
  • the SBL88 group showed a high average body temperature with a statistically significant difference from the control group. Further, in the stress breeding period, the difference in average body temperature between the SBL88 group and the control group was more remarkable than in the non-stress breeding period. In the control group, it was observed that when stress was applied, the average body temperature gradually decreased greatly compared to the non-stress breeding period. On the other hand, in the SBL88 group, even when stress was applied, a decrease in body temperature was suppressed and a body temperature closer to normal was maintained. The difference in average body temperature between the SBL88 group and the control group was 1 ° C. or less under both unstressed and stressed conditions.
  • the body temperature was able to be raised moderately by administration of the cell-treated product of SBL88. Moreover, in the stress load state, the fall of body temperature was able to be suppressed by administration of the microbial cell processed material of SBL88.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Husbandry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne un agent d'élévation de la température corporelle comprenant comme ingrédient actif la cellule bactérienne de la souche SBC8803 (no de dépôt : FERM BP-10632) appartenant au genre Lactobacillus brevis, ou son produit traité.
PCT/JP2014/058520 2013-06-13 2014-03-26 Agent d'élévation de la température corporelle WO2014199698A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013124849A JP6671652B2 (ja) 2013-06-13 2013-06-13 体温上昇剤
JP2013-124849 2013-06-13

Publications (1)

Publication Number Publication Date
WO2014199698A1 true WO2014199698A1 (fr) 2014-12-18

Family

ID=52022004

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2014/058520 WO2014199698A1 (fr) 2013-06-13 2014-03-26 Agent d'élévation de la température corporelle

Country Status (2)

Country Link
JP (1) JP6671652B2 (fr)
WO (1) WO2014199698A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008023663A1 (fr) * 2006-08-21 2008-02-28 Sapporo Breweries Limited Souche bactérienne possédant une activité anti-allergique, et boisson, aliment et agent anti-allergique comprenant une cellule de la souche bactérienne

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6067292B2 (ja) * 2012-03-19 2017-01-25 サッポロビール株式会社 セロトニン分泌促進剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008023663A1 (fr) * 2006-08-21 2008-02-28 Sapporo Breweries Limited Souche bactérienne possédant une activité anti-allergique, et boisson, aliment et agent anti-allergique comprenant une cellule de la souche bactérienne

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Taion o Agete Men'ekiryoku Up", SAWAI.CO, 17 April 2014 (2014-04-17), Retrieved from the Internet <URL:http://www.sawai.co.jp/kenko-suishinka/illness/200909-02.html> [retrieved on 20140417] *
AYUMI YAHADA ET AL.: "Effect of y-aminobutyric Acid (GABA) on Human Mental Stress: Examination with Salivary Human Chromogranin A and a- amylase as Bio-markers", NAKAMURA GAKUEN UNIVERSITY, 2012, pages 261 - 268 *

Also Published As

Publication number Publication date
JP2015000851A (ja) 2015-01-05
JP6671652B2 (ja) 2020-03-25

Similar Documents

Publication Publication Date Title
JP6799673B2 (ja) 炎症制御遺伝子の発現促進用組成物
TWI359668B (fr)
EP2475764B1 (fr) Matériau probiotique
AU2005232497A1 (en) Preventive and/or therapeutic agent for inflammatory bowel diseases
KR102543494B1 (ko) 신규 프로바이오틱스 및 이의 용도
US20160303226A1 (en) Heat-treated formulation of bifidobacterium lactis ncc 2818 reduces allergic manifestations
WO2009090961A1 (fr) Agent de prévention d&#39;une hépatopathie alcoolique
JP5945092B2 (ja) 中性脂肪低減剤
JP4565057B2 (ja) イムノグロブリンａ誘導能の高い新規乳酸菌
JP5943342B2 (ja) 概日リズム改善剤
KR20140026326A (ko) 신장 기능을 강화시키는 조성물 및 방법
JP5967527B2 (ja) 食欲増進かつ体重増加抑制剤
JP5209294B2 (ja) インターロイキン１２産生促進剤
JP6261688B2 (ja) Ｑｏｌ改善又は持続剤
JP7430312B2 (ja) 腸内短鎖脂肪酸産生促進用組成物及びこれを含む飲食品
JP2023023981A (ja) 生体内のＩｇＡとＩＦＮ－γ産生を促進する乳酸菌製剤及び経口組成物
WO2014199698A1 (fr) Agent d&#39;élévation de la température corporelle
JP6298912B1 (ja) 乳酸菌の製造方法、及び免疫調節用組成物
KR20220079092A (ko) 신규 균주를 포함하는 염증성 질환 예방 또는 치료용 조성물
JP6671950B2 (ja) 機能性胃腸症改善剤
JP5815105B2 (ja) 中性脂肪低減剤
JP6487106B1 (ja) 免疫機能向上用食品組成物
JP6594623B2 (ja) ノロウイルス感染予防剤
TW202335676A (zh) 腸管免疫賦活劑及IgA產生促進劑
Subhashree Development of plant base probiotic nutritional supplement to enhance gut probiotic microflora

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14811571

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14811571

Country of ref document: EP

Kind code of ref document: A1